Cargando…

Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer

Prognostic markers currently utilized in clinical practice for estrogen receptor-positive (ER+) and lymph node-negative (LN−) invasive breast cancer (IBC) patients include the Nottingham grading system and Oncotype Dx (ODx). However, these biomarkers are not always optimal and remain subject to inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuli, Li, Haojia, Janowczyk, Andrew, Toro, Paula, Corredor, Germán, Whitney, Jon, Lu, Cheng, Koyuncu, Can F., Mokhtari, Mojgan, Buzzy, Christina, Ganesan, Shridar, Feldman, Michael D., Fu, Pingfu, Corbin, Haley, Harbhajanka, Aparna, Gilmore, Hannah, Goldstein, Lori J., Davidson, Nancy E., Desai, Sangeeta, Parmar, Vani, Madabhushi, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192429/
https://www.ncbi.nlm.nih.gov/pubmed/37198173
http://dx.doi.org/10.1038/s41523-023-00545-y
_version_ 1785043627005706240
author Chen, Yuli
Li, Haojia
Janowczyk, Andrew
Toro, Paula
Corredor, Germán
Whitney, Jon
Lu, Cheng
Koyuncu, Can F.
Mokhtari, Mojgan
Buzzy, Christina
Ganesan, Shridar
Feldman, Michael D.
Fu, Pingfu
Corbin, Haley
Harbhajanka, Aparna
Gilmore, Hannah
Goldstein, Lori J.
Davidson, Nancy E.
Desai, Sangeeta
Parmar, Vani
Madabhushi, Anant
author_facet Chen, Yuli
Li, Haojia
Janowczyk, Andrew
Toro, Paula
Corredor, Germán
Whitney, Jon
Lu, Cheng
Koyuncu, Can F.
Mokhtari, Mojgan
Buzzy, Christina
Ganesan, Shridar
Feldman, Michael D.
Fu, Pingfu
Corbin, Haley
Harbhajanka, Aparna
Gilmore, Hannah
Goldstein, Lori J.
Davidson, Nancy E.
Desai, Sangeeta
Parmar, Vani
Madabhushi, Anant
author_sort Chen, Yuli
collection PubMed
description Prognostic markers currently utilized in clinical practice for estrogen receptor-positive (ER+) and lymph node-negative (LN−) invasive breast cancer (IBC) patients include the Nottingham grading system and Oncotype Dx (ODx). However, these biomarkers are not always optimal and remain subject to inter-/intra-observer variability and high cost. In this study, we evaluated the association between computationally derived image features from H&E images and disease-free survival (DFS) in ER+ and LN− IBC. H&E images from a total of n = 321 patients with ER+ and LN− IBC from three cohorts were employed for this study (Training set: D1 (n = 116), Validation sets: D2 (n = 121) and D3 (n = 84)). A total of 343 features relating to nuclear morphology, mitotic activity, and tubule formation were computationally extracted from each slide image. A Cox regression model (IbRiS) was trained to identify significant predictors of DFS and predict a high/low-risk category using D1 and was validated on independent testing sets D2 and D3 as well as within each ODx risk category. IbRiS was significantly prognostic of DFS with a hazard ratio (HR) of 2.33 (95% confidence interval (95% CI) = 1.02–5.32, p = 0.045) on D2 and a HR of 2.94 (95% CI = 1.18–7.35, p = 0.0208) on D3. In addition, IbRiS yielded significant risk stratification within high ODx risk categories (D1 + D2: HR = 10.35, 95% CI = 1.20–89.18, p = 0.0106; D1: p = 0.0238; D2: p = 0.0389), potentially providing more granular risk stratification than offered by ODx alone.
format Online
Article
Text
id pubmed-10192429
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101924292023-05-19 Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer Chen, Yuli Li, Haojia Janowczyk, Andrew Toro, Paula Corredor, Germán Whitney, Jon Lu, Cheng Koyuncu, Can F. Mokhtari, Mojgan Buzzy, Christina Ganesan, Shridar Feldman, Michael D. Fu, Pingfu Corbin, Haley Harbhajanka, Aparna Gilmore, Hannah Goldstein, Lori J. Davidson, Nancy E. Desai, Sangeeta Parmar, Vani Madabhushi, Anant NPJ Breast Cancer Article Prognostic markers currently utilized in clinical practice for estrogen receptor-positive (ER+) and lymph node-negative (LN−) invasive breast cancer (IBC) patients include the Nottingham grading system and Oncotype Dx (ODx). However, these biomarkers are not always optimal and remain subject to inter-/intra-observer variability and high cost. In this study, we evaluated the association between computationally derived image features from H&E images and disease-free survival (DFS) in ER+ and LN− IBC. H&E images from a total of n = 321 patients with ER+ and LN− IBC from three cohorts were employed for this study (Training set: D1 (n = 116), Validation sets: D2 (n = 121) and D3 (n = 84)). A total of 343 features relating to nuclear morphology, mitotic activity, and tubule formation were computationally extracted from each slide image. A Cox regression model (IbRiS) was trained to identify significant predictors of DFS and predict a high/low-risk category using D1 and was validated on independent testing sets D2 and D3 as well as within each ODx risk category. IbRiS was significantly prognostic of DFS with a hazard ratio (HR) of 2.33 (95% confidence interval (95% CI) = 1.02–5.32, p = 0.045) on D2 and a HR of 2.94 (95% CI = 1.18–7.35, p = 0.0208) on D3. In addition, IbRiS yielded significant risk stratification within high ODx risk categories (D1 + D2: HR = 10.35, 95% CI = 1.20–89.18, p = 0.0106; D1: p = 0.0238; D2: p = 0.0389), potentially providing more granular risk stratification than offered by ODx alone. Nature Publishing Group UK 2023-05-17 /pmc/articles/PMC10192429/ /pubmed/37198173 http://dx.doi.org/10.1038/s41523-023-00545-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Chen, Yuli
Li, Haojia
Janowczyk, Andrew
Toro, Paula
Corredor, Germán
Whitney, Jon
Lu, Cheng
Koyuncu, Can F.
Mokhtari, Mojgan
Buzzy, Christina
Ganesan, Shridar
Feldman, Michael D.
Fu, Pingfu
Corbin, Haley
Harbhajanka, Aparna
Gilmore, Hannah
Goldstein, Lori J.
Davidson, Nancy E.
Desai, Sangeeta
Parmar, Vani
Madabhushi, Anant
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer
title Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer
title_full Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer
title_fullStr Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer
title_full_unstemmed Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer
title_short Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer
title_sort computational pathology improves risk stratification of a multi-gene assay for early stage er+ breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192429/
https://www.ncbi.nlm.nih.gov/pubmed/37198173
http://dx.doi.org/10.1038/s41523-023-00545-y
work_keys_str_mv AT chenyuli computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT lihaojia computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT janowczykandrew computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT toropaula computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT corredorgerman computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT whitneyjon computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT lucheng computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT koyuncucanf computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT mokhtarimojgan computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT buzzychristina computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT ganesanshridar computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT feldmanmichaeld computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT fupingfu computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT corbinhaley computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT harbhajankaaparna computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT gilmorehannah computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT goldsteinlorij computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT davidsonnancye computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT desaisangeeta computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT parmarvani computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer
AT madabhushianant computationalpathologyimprovesriskstratificationofamultigeneassayforearlystageerbreastcancer